Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC) DOI Creative Commons

Ahmed Mousa,

Alexander Enk, Jessica C. Hassel

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(19), P. 1615 - 1615

Published: Sept. 26, 2024

Non-melanoma skin cancer (NMSC) is primarily categorized into basal cell carcinoma (BCC), the most prevalent form of cancer, and cutaneous squamous (cSCC), second common type. Both BCC cSCC represent a significant health burden, particularly in immunocompromised individuals elderly. The immune system plays pivotal role development progression NMSC, making it critical focus for therapeutic interventions. This review highlights key immunological targets cSCC, with on checkpoint molecules such as PD-1/PD-L1 CTLA-4, which regulate T activity contribute to evasion. also anti-tumor subsets within tumor microenvironment (TME), tumor-infiltrating lymphocytes (TILs) dendritic cells. Additionally, examines immunosuppressive elements TME, including regulatory cells (Tregs), myeloid-derived suppressor (MDSCs), tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), well their roles NMSC resistance therapy. Emerging strategies targeting these elements, monoclonal antibodies, are discussed potential enhance responses improve clinical outcomes. By elucidating landscape drawing comparisons melanoma, this transformative immunotherapy treating malignancies.

Language: Английский

Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC) DOI Creative Commons

Ahmed Mousa,

Alexander Enk, Jessica C. Hassel

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(19), P. 1615 - 1615

Published: Sept. 26, 2024

Non-melanoma skin cancer (NMSC) is primarily categorized into basal cell carcinoma (BCC), the most prevalent form of cancer, and cutaneous squamous (cSCC), second common type. Both BCC cSCC represent a significant health burden, particularly in immunocompromised individuals elderly. The immune system plays pivotal role development progression NMSC, making it critical focus for therapeutic interventions. This review highlights key immunological targets cSCC, with on checkpoint molecules such as PD-1/PD-L1 CTLA-4, which regulate T activity contribute to evasion. also anti-tumor subsets within tumor microenvironment (TME), tumor-infiltrating lymphocytes (TILs) dendritic cells. Additionally, examines immunosuppressive elements TME, including regulatory cells (Tregs), myeloid-derived suppressor (MDSCs), tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), well their roles NMSC resistance therapy. Emerging strategies targeting these elements, monoclonal antibodies, are discussed potential enhance responses improve clinical outcomes. By elucidating landscape drawing comparisons melanoma, this transformative immunotherapy treating malignancies.

Language: Английский

Citations

4